Oxford BioMedica

Axovant reaps the rewards from its gene therapy refocus

Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.

February 07, 2019

Sanofi does a spring clean

The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.

July 09, 2018

Not developing your gene therapy? Call Axovant

Axovant's need to rebuild its pipeline is benefiting gene therapy developers.

June 06, 2018

Axovant looks to Oxford Biomedica for gene therapy resurrection

Axovant transforms itself into a new gene therapy company with an old Oxford Biomedica product.

March 22, 2018

Therapy focus – Novel Parkinson’s projects gather pace

August 30, 2017

World’s first CAR-T approval sweeps away more cell therapy doubts

August 11, 2017

Ionis absorbs Glaxo rare disease cull

July 13, 2017

Novartis’s CAR speeds towards approval with panel nod

July 11, 2017

The CTL019 adcom mists begin to clear

July 07, 2017

Snippet roundup: Oxford jumps on Novartis's CAR-T and EU regulators think for themselves

May 05, 2017

Snippet roundup: Novartis's allogeneic CAR-T drive and Astra's IL-4 interest

Load More